Evaluation of the Pharmacokinetics and Hepatoprotective Effects of Phillygenin in Mouse

Figure 3

Effect of phillygenin/OFE on liver histopathology of CCl₄-intoxicated mice. (a) Normal group liver section; (b) liver section of CCl₄-intoxicated group; (c) liver section of bifendate + CCl₄ treated group; (d) liver section of phillygenin (6 mg/kg) + CCl₄-treated group; (e) liver section of phillygenin (12 mg/kg) + CCl₄-treated group; (f) liver section of phillygenin (24 mg/kg) + CCl₄-treated group. (g) Liver section of OFE (150 mg/kg) + CCl₄-treated group; (h) liver section of OFE (300 mg/kg) + CCl₄-treated group; (i) liver section of OFE (600 mg/kg) + CCl₄-treated group. Original magnification 200× (a, b, c, d, e, and f).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)